What is the 13F Pro Quality Score for RCKT?

13F Pro ranks ROCKET PHARMACEUTICALS, INC. (RCKT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RCKT's current score at https://13fpro.ai/research/RCKT (free sign-up required for the full ranking).

Which hedge funds own the most RCKT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RCKT include RTW INVESTMENTS,, BlackRock,, CITIGROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RCKT as soon as new 13F filings post.

Where does 13F Pro source RCKT data?

All ROCKET PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. ROCKET PHARMACEUTICALS, INC. files with the SEC under CIK 1281895. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RCKT in?

ROCKET PHARMACEUTICALS, INC. (RCKT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RCKT research updated on 13F Pro?

RCKT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ROCKET PHARMACEUTICALS, INC.(RCKT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1281895 RCKT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RCKT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ROCKET PHARMACEUTICALS, INC. (RCKT), a Healthcare sector company. RCKT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), ROCKET PHARMACEUTICALS, INC. reports net income of $-47.6M, free cash flow of $-45.5M. Top institutional holders of RCKT by reported 13-F value include RTW INVESTMENTS,, BlackRock,, CITIGROUP, based on the most recent SEC filings. RCKT trades on the Nasdaq exchange and files with the SEC under CIK 1281895. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCKT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ROCKET PHARMACEUTICALS, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-47.6M

Free Cash Flow

Q1 2026

$-45.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY22 $0.00FY23 $0.00FY24 $0.00FY25 $0.00

Net Income

+13.8% YoY

$-223.1MFY 2025

FY22 $-221.9MFY23 $-245.6MFY24 $-258.7MFY25 $-223.1M

Operating Income

+15.2% YoY

$-231.7MFY 2025

FY22 $-224.3MFY23 $-259.7MFY24 $-273.2MFY25 $-231.7M

EPS (Diluted)

+26.4% YoY

$-2.01FY 2025

FY22 $-3.26FY23 $-2.92FY24 $-2.73FY25 $-2.01

Total Assets

-37.4% YoY

$330.4MFY 2025

FY22 $551.8MFY23 $566.3MFY24 $527.7MFY25 $330.4M

Op. Cash Flow

+9.4% YoY

$-190.0MFY 2025

FY22 $-178.1MFY23 $-194.9MFY24 $-209.7MFY25 $-190.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	$-223.1M +13.8%	$-258.7M -5.4%	$-245.6M -10.7%	$-221.9M -31.2%	$-169.1M -21.0%	$-139.7M
Operating Income	$-231.7M +15.2%	$-273.2M -5.2%	$-259.7M -15.7%	$-224.3M -34.1%	$-167.2M -24.5%	$-134.3M
EPS (Diluted)	$-2.01 +26.4%	$-2.73 +6.5%	$-2.92 +10.4%	$-3.26 -22.1%	$-2.67 -6.0%	$-2.52
Total Assets	$330.4M -37.4%	$527.7M -6.8%	$566.3M +2.6%	$551.8M +11.0%	$497.0M -15.9%	$590.8M
Operating Cash Flow	$-190.0M +9.4%	$-209.7M -7.6%	$-194.9M -9.4%	$-178.1M -47.0%	$-121.2M -62.3%	$-74.6M

AI Insight: RCKT Financial Trends

Rocket remains pre-revenue with equity eroding to $238M in Q1 2026, though quarterly cash burn has moderated meaningfully from peak losses.

• Operating loss narrowed from -$74M in Q2 2024 to -$44M in Q4 2025, a meaningful reduction in quarterly burn rate.

• Revenue remains $0M across all eight quarters — no commercial product contribution to date.

• Equity has declined steadily from $463M in Q4 2024 to $238M in Q1 2026, a $225M deterioration in three quarters.

⚠ At the Q1 2026 cash burn rate of ~$45M/quarter, the $238M equity base implies a constrained runway without new financing.

⚠ Operating loss ticked back up to -$49M in Q1 2026 from -$44M in Q4 2025 — watch for renewed burn acceleration.

AI Insight: RCKT Ratio Trends

RCKT's return metrics remain deeply negative across all periods, with ROE worsening to -80.0% in Q1 2026 after a brief improvement in Q4 2024.

• ROE deteriorated from -61.4% in Q4 2025 to -80.0% in Q1 2026, reversing three quarters of relative stabilization.

• ROIC swung from a local trough of -90.7% (TTM) versus a relative peak of -54.1% in Q4 2024, showing no sustained improvement.

• ROA has tracked between -45.7% and -73.4% over the observed periods, with no clear directional improvement trend.

⚠ Q1 2026 ROIC of -81.5% is the worst single-quarter reading outside the TTM figure — momentum is re-deteriorating.

⚠ OpMargin, NPM, and D/E data are entirely absent; leverage and profitability trajectory cannot be assessed without them.

Get alerted when RCKT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ROCKET PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RCKT

RTW INVESTMENTS, LP
$63.3M17,687,772 sh
BlackRock, Inc.
$28.0M7,834,795 sh
CITIGROUP INC
$18.3M5,107,708 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$16.8M4,690,215 sh
STATE STREET CORP
$16.1M4,485,989 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.5M3,775,736 sh
MAVERICK CAPITAL LTD
$12.8M3,567,372 sh
Newtyn Management, LLC
$11.3M3,165,900 sh
Nuveen, LLC
$11.2M3,128,753 sh
MILLENNIUM MANAGEMENT LLC
$11.2M3,118,124 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$63.3M	17,687,772
BlackRock, Inc.	$28.0M	7,834,795
CITIGROUP INC	$18.3M	5,107,708
VANGUARD PORTFOLIO MANAGEMENT LLC	$16.8M	4,690,215
STATE STREET CORP	$16.1M	4,485,989
VANGUARD CAPITAL MANAGEMENT LLC	$13.5M	3,775,736
MAVERICK CAPITAL LTD	$12.8M	3,567,372
Newtyn Management, LLC	$11.3M	3,165,900
Nuveen, LLC	$11.2M	3,128,753
MILLENNIUM MANAGEMENT LLC	$11.2M	3,118,124

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RCKT on your watchlist

Track score changes the day ROCKET PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RCKT a good stock to buy?

13F Pro's AI-powered analysis of ROCKET PHARMACEUTICALS, INC. (RCKT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RCKT are available on the RCKT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RCKT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RCKT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ROCKET PHARMACEUTICALS, INC.'s investment landscape.